Detalhe da pesquisa
1.
Early Relief of Pruritus in Atopic Dermatitis with Crisaborole Ointment, A Non-steroidal, Phosphodiesterase 4 Inhibitor.
Acta Derm Venereol
; 98(5): 484-489, 2018 Apr 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-29363715
2.
Long-term safety of crisaborole ointment 2% in children and adults with mild to moderate atopic dermatitis.
J Am Acad Dermatol
; 77(4): 641-649.e5, 2017 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-28823881
3.
Tavaborole in Difficult-to-Treat Onychomycosis Cases: A Post-hoc Assessment of Phase III Subjects.
J Drugs Dermatol
; 16(10): 1016-1021, 2017 Oct 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29036255
4.
Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults.
J Am Acad Dermatol
; 75(3): 494-503.e6, 2016 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-27417017
5.
Evaluation of the Appearance of Nail Polish Following Daily Treatment of Ex Vivo Human Fingernails With Topical Solutions of Tavaborole or Efinaconazole.
J Drugs Dermatol
; 15(1): 89-94, 2016 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-26741386
6.
Crisaborole Topical Ointment, 2%: A Nonsteroidal, Topical, Anti-Inflammatory Phosphodiesterase 4 Inhibitor in Clinical Development for the Treatment of Atopic Dermatitis.
J Drugs Dermatol
; 15(4): 390-6, 2016 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-27050693
7.
Post Hoc Analyses of the Effect of Crisaborole Topical Ointment, 2% on Atopic Dermatitis: Associated Pruritus from Phase 1 and 2 Clinical Studies.
J Drugs Dermatol
; 15(2): 172-6, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-26885784
8.
Pharmacokinetic Profile, Safety, and Tolerability of Crisaborole Topical Ointment, 2% in Adolescents with Atopic Dermatitis: An Open-Label Phase 2a Study.
Pediatr Dermatol
; 33(2): 150-9, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-26777394
9.
Crisaborole Topical Ointment, 2% in Patients Ages 2 to 17 Years with Atopic Dermatitis: A Phase 1b, Open-Label, Maximal-Use Systemic Exposure Study.
Pediatr Dermatol
; 33(4): 380-7, 2016 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-27193740
10.
Antifungal agents for onychomycosis: new treatment strategies to improve safety.
Dermatol Online J
; 22(3)2016 Mar 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-27136621
11.
Efficacy and safety of tavaborole topical solution, 5%, a novel boron-based antifungal agent, for the treatment of toenail onychomycosis: Results from 2 randomized phase-III studies.
J Am Acad Dermatol
; 73(1): 62-9, 2015 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-25956661
12.
Crisaborole Topical Ointment, 2% in Adults With Atopic Dermatitis: A Phase 2a, Vehicle-Controlled, Proof-of-Concept Study.
J Drugs Dermatol
; 14(10): 1108-12, 2015 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-26461821
13.
In Vitro Nail Penetration and Antifungal Activity of Tavaborole, a Boron-Based Pharmaceutical.
J Drugs Dermatol
; 14(6): 609-14, 2015 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-26091387
14.
In Vitro Nail Penetration of Tavaborole Topical Solution, 5%, Through Nail Polish on Ex Vivo Human Fingernails.
J Drugs Dermatol
; 14(7): 675-8, 2015 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-26151782
15.
A Phase 2, Randomized, Controlled, Dose-Ranging Study Evaluating Crisaborole Topical Ointment, 0.5% and 2% in Adolescents With Mild to Moderate Atopic Dermatitis.
J Drugs Dermatol
; 14(12): 1394-9, 2015 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-26659931
16.
The efficacy and safety of tavaborole, a novel, boron-based pharmaceutical agent: phase 2 studies conducted for the topical treatment of toenail onychomycosis.
J Drugs Dermatol
; 13(9): 1124-32, 2014 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-25226015
17.
Age-related differences in the reproductive and metabolic implications of polycystic ovarian syndrome: findings in an obese, United States population.
Gynecol Endocrinol
; 28(10): 819-22, 2012 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-22475130
18.
Comparative efficacy of nonpurpuragenic pulsed dye laser and intense pulsed light for erythematotelangiectatic rosacea.
Dermatol Surg
; 35(6): 920-8, 2009 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-19397667
19.
Recent advances in acne vulgaris research: insights and clinical implications.
Adv Dermatol
; 24: 197-209, 2008.
Artigo
em Inglês
| MEDLINE | ID: mdl-19256310
20.
Evaluation of the efficacy and safety of tavaborole topical solution, 5%, in the treatment of onychomycosis of the toenail in adults: a pooled analysis of an 8-week, post-study follow-up from two randomized phase 3 studies.
J Dermatolog Treat
; 29(1): 44-48, 2018 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-28521541